Latest Governance News

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

CVC Limited has reversed its fortunes with a $0.5 million net profit after tax for FY25, driven by strong property investment income and strategic land developments, while maintaining a cautious capital management approach and withholding dividends.

Ironbark Capital Limited reported a 17.6% increase in net profit for FY2025, driven by higher investment income and realised gains, alongside a raised fully franked dividend and an extended share buy-back program.

Eildon Capital Group reported a net loss of $5.7 million for FY2025, weighed down by significant one-off impairments, while pivoting to focused real estate investments with a new $20.8 million joint venture in Queensland.

Wagners Holding Company Limited reported a 120% increase in net profit after tax for FY25 despite a 10.4% revenue decline, driven by strong segment performance and cost management. The company also declared a higher fully franked final dividend of 3.2 cents per share.

Atturra Limited has become the first Australian Microsoft Solutions Partner to earn the Private Cloud Solution Partner designation, underscoring its leadership in sovereign and hybrid cloud services for critical sectors.

Marvel Gold Limited has restructured its Mali asset sale with Anchises Capital, securing a $250,000 equity injection while revising terms for its Tabakorole Gold Project sale.

WCM Global Growth Limited reported a robust 53% rise in net profit for FY2025, driven by strong portfolio returns and a successful capital raise, prompting an increased final dividend and upward revision of future dividends.

Star Combo Pharma has reported a remarkable jump in profit for FY2025, driven by strong revenue growth and a settled insurance claim, while declaring its second dividend and planning production expansion.

Star Combo Pharma Limited reported a 7% increase in total revenue to $27.8 million for FY25, propelled by a 10% rise in its core OEM and Own Brands segment. The company’s profit before tax surged to $5.31 million, reflecting operational strength despite challenges in its Retail division.

Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.